MNKD MannKind Corporation

4.05
-0.01 (-0.25%)
Sep 25 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Period:

Draw Mode:

Volume 1,624,609
Bid Price 3.99
Ask Price 4.06
News -
Day High 4.08

Low
2.91

52 Week Range

High
5.75

Day Low 3.99
Company Name Stock Ticker Symbol Market Type
MannKind Corporation MNKD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.25% 4.05 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.08 3.99 4.08 4.01 4.06
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,061 1,624,609 $ 4.03 $ 6,554,913 - 2.91 - 5.75
Last Trade Time Type Quantity Stock Price Currency
18:39:21 formt 114 $ 4.05 USD

MannKind (MNKD) Options Flow Summary

Overall Flow

Bullish

Net Premium

53k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

1.00%

MannKind Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.09B 268.36M - 99.77M -87.4M -0.33 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

MannKind News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MNKD Message Board. Create One! See More Posts on MNKD Message Board See More Message Board Posts

Historical MNKD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.454.643.994.192,410,968-0.40-8.99%
1 Month4.724.943.994.392,466,447-0.67-14.19%
3 Months3.955.753.894.712,746,2050.102.53%
6 Months4.045.753.704.402,951,9390.010.25%
1 Year3.085.752.914.403,462,5290.9731.49%
3 Years1.866.251.784.083,790,0382.19117.74%
5 Years1.956.250.803.273,294,9622.10107.69%

MannKind Description

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.